SCHEMBL19770588

SCHEMBL19770588

CC(C)OC1OC(CO)C(O)C1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 1/20 0.47
TYR P14679 3/20 0.47
ALDH1A1 P00352 1/20 0.47
THRB P10828 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
GAA P10253 1/20 0.44
PRKD3 O94806 1/20 0.43
PRKCG P05129 1/20 0.43
PRKCB P05771 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCH P24723 1/20 0.43
PRKCI P41743 1/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCZ Q05513 1/20 0.43
PRKCD Q05655 1/20 0.43
PRKD1 Q15139 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022664 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL10388282 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL26727391 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL20027477 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL16678815 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL14690893 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL24943577 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL10388284 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL14690973 1.00 L3MBTL1 (0.49) L3MBTL1MAPTTYRALDH1A1THRB
SCHEMBL20713712 0.98 L3MBTL1 (0.51) L3MBTL1MAPTTYRALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11000512-B2 Use of DDX3 inhibitors as antiproliferative agents AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2021-05-11 US disclosed
US-10941121-B2 Human helicase DDX3 inhibitors as therapeutic agents AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2021-03-09 US disclosed
US-20200140398-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2020-05-07 US disclosed
US-20190099403-A1 USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) 2019-04-04 US disclosed
US-20180016243-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2018-01-18 US disclosed
US-20180016243-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11000512-B2 Use of DDX3 inhibitors as antiproliferative agents DDX3X, DDX21, DDB1 L3MBTL1 1706/4885MAPT 4194/4885TYR 3853/4885
US-20180016243-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS DDX3X, DDX39B, DDX1 L3MBTL1 669/4885MAPT 3432/4885TYR 4659/4885
US-20200140398-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS DDX3X, DDX39B, DDX1 L3MBTL1 669/4885MAPT 3432/4885TYR 4659/4885
US-10941121-B2 Human helicase DDX3 inhibitors as therapeutic agents DDX3X, DDX39B, DDX1 L3MBTL1 669/4885MAPT 3432/4885TYR 4659/4885
US-20190099403-A1 USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS DDX21, DDX3X, DDB1 L3MBTL1 1528/4885MAPT 4136/4885TYR 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.